September 11, 2017

Biohit secures important patent in Japan

Biohit's focus lies in innovative products and services that promote research and early diagnosis in the healthcare sector.
Biohit's focus lies in innovative products and services that promote research and early diagnosis in the healthcare sector.
Screenshot/Biohit Annual Report 2016

Finnish biotechnology company Biohit has been granted a patent for its Biohit Acetium Capsule in Japan. The Biohit Acetium Capsule binds acetaldehyde in the stomach and is used to treat acid-free stomach and those at risk of obtaining gastric cancer.

Biohit’s patent titled: ‘Composition and method for binding acetaldehyde in stomach’ is valid until 22 May 2027 and covers all fields of application of the Biohit Acetium Capsule as well as any eventual future composition modifications, dosage and indications for use.

The Biohit Acetium Capsule is a non-toxic composition which binds acetaldehyde found in the stomach, intestine and/or colon. The composition especially benefits people at risk of gastric cancer.

“In Japan, gastric cancer has ranked as the most common cancer by both incidence and mortality for the last several decades,” says Semi Korpela, CEO of Biohit. “With a rational combined use of GastroPanel (diagnosis) and Acetium Capsule (prevention), one can diagnose the gastric cancer risks groups and subsequently protect their stomach against carcinogenic acetaldehyde exposure.”

Share: